期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 147, 期 3, 页码 347-351出版社
WILEY-BLACKWELL PUBLISHING, INC
DOI: 10.1111/j.1365-2141.2009.07864.x
关键词
myeloma; TP53; bortezomib; prognosis; genomics
类别
资金
- NCI NIH HHS [CA55819, P01 CA055819] Funding Source: Medline
P>Contrary to Total Therapy (TT) 2 for multiple myeloma patients, FGFR3- translocation bore no adverse effects on outcome in TT3 with added bortezomib. Del TP53, another poor-risk feature in TT2 and present in 10% of 441 patients treated, was examined for its prognostic consequences in TT3. Not affecting rate or duration of complete response, TP53 haplo-insufficiency also did not compromise, in the 83% with genomically defined low-risk myeloma, survival or event-free survival. FGFR3+ and FGFR3- molecular subgroups fared worse in the presence of del TP53 when applying TT2 but not TT3. Thus, the prognostic implications of del TP53 were protocol-, genome-defined risk- and molecular subgroup-dependent.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据